Recruiting Lymphoma Studies in Columbus
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin...
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies....
AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lympho...
Epcoritamab and Rituximab for First-line Follicular Lymphoma
The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other trea...
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders....
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
This study is planned as a single arm clinical trial of tazemetostat in combination with bendamustine and rituximab with both a phase I and phase II component. All patients will receive tazemetostat t...
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
This phase Ib/II trial evaluates the safety, optimal dose, and efficacy of the combination of epcoritamab and ibrutinib in treating patients with aggressive B-cell non-Hodgkin lymphoma that has come b...
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lym...
About Lymphoma Clinical Trials in Columbus
Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.
There are currently 8 lymphoma clinical trials recruiting participants in Columbus, IN. These studies are seeking a combined 1,322 participants. Research is being sponsored by Hoffmann-La Roche, AstraZeneca, Reid Merryman, MD and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Lymphoma Clinical Trials in Columbus — FAQ
Are there lymphoma clinical trials in Columbus?
Yes, there are 8 lymphoma clinical trials currently recruiting in Columbus, IN. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Columbus?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Columbus research site will contact you about next steps.
Are clinical trials in Columbus free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Columbus studies also compensate for your time and travel.
What lymphoma treatments are being tested?
The 8 active trials in Columbus are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.
Data updated March 2, 2026 from ClinicalTrials.gov